Jack Cuzick, PhD; Orrin Myers, PhD; Ji-Hyun Lee, DrPH; et al.
open access
JAMA Oncol. 2017;3(10):1327-1334. doi:10.1001/jamaoncol.2017.1040
This study examines 5-year outcomes after cytology showing atypical squamous cells of undetermined significance among women with vs without human papillomavirus testing.
Arvind Dasari, MD, MS; Chan Shen, PhD; Daniel Halperin, MD; et al.
free access
has audio
JAMA Oncol. 2017;3(10):1335-1342. doi:10.1001/jamaoncol.2017.0589
This population-based study evaluates SEER data on the incidence and prevalence of neuroendocrine tumors over 20 years.
-
Podcast:
Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors (JAMA Oncology)
-
Podcast:
Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors
-
Invited Commentary
Understanding Neuroendocrine Tumors鈥擜 NET Gain
Pamela L. Kunz, MD
JAMA Oncol
Joseph M. Unger, PhD, MS; Michael LeBlanc, PhD; Charles D. Blanke, MD
free access
JAMA Oncol. 2017;3(10):1345-1351. doi:10.1001/jamaoncol.2017.0762
Using study data from SWOG, this study examines the extent to which positive National Cancer Institute鈥搒ponsored cancer treatment trials have benefited patients with cancer in the US population.
Monica Morrow, MD; Paul Abrahamse, MA; Timothy P. Hofer, MD; et al.
free access
has audio
JAMA Oncol. 2017;3(10):1352-1357. doi:10.1001/jamaoncol.2017.0774
This cohort study describes surgeons鈥� approach to surgical margins for invasive breast cancer, changes in postlumpectomy surgery rates, and final surgical treatment following a 2014 consensus statement endorsing a margin of 鈥渘o ink on tumor.鈥�
-
Podcast:
Trends in Reoperation After Initial Lumpectomy for Breast Cancer
Feng-Ming Kong, MD, PhD; Randall K. Ten Haken, PhD; Matthew Schipper, PhD; et al.
free access
JAMA Oncol. 2017;3(10):1358-1365. doi:10.1001/jamaoncol.2017.0982
This clinical trial examines whether adaptive radiation therapy can target high-dose radiation to the 18F-fludeoxyglucose (FDG)-avid tumor on midtreatment FDG鈥損ositron emission tomography with computed tomography to improve local tumor control of locally advanced non鈥搒mall-cell lung cancer.
Rakesh Jalali, MD; Tejpal Gupta, MD; Jayant S. Goda, MD; et al.
free access
JAMA Oncol. 2017;3(10):1368-1376. doi:10.1001/jamaoncol.2017.0997
This phase 3 randomized clinical trial compares neurocognitive and endocrine functional outcomes and survival at 5 years in young patients with residual and/or progressive benign or low-grade brain tumors treated with stereotactic conformal radiotherapy or conventional radiotherapy techniques.
Eric Hahnen, PhD; Bianca Lederer, PhD; Jan Hauke, PhD; et al.
free access
JAMA Oncol. 2017;3(10):1378-1385. doi:10.1001/jamaoncol.2017.1007
This secondary analysis of a randomized clinical trial examines DNA samples and family history of patients with triple-negative breast cancer to determine response to and survival from neoadjuvant treatment.
-
Editorial
Use of Neoadjuvant Platinum鈥擳he Ongoing Conundrum
Hope S. Rugo, MD; Karen Gelmon, MD, FCRP
JAMA Oncol
Safiya Karim, MD; Kelly Brennan, MSc; Sulaiman Nanji, MD, PhD; et al.
free access
JAMA Oncol. 2017;3(10):1386-1392. doi:10.1001/jamaoncol.2017.1016
This population-based cohort study explores differences in laterality based on disease characteristics and outcomes in a population-based cohort of early-stage colon cancer.
Donna R. Rivera, PharmD, MSc; Lisa Gallicchio, PhD; Jeremy Brown, MD; et al.
free access
online only
has audio
JAMA Oncol. 2017;3(10):e172450. doi:10.1001/jamaoncol.2017.2450
This data analysis estimates the proportion of US emergency department visits made by adults with a cancer diagnosis and examines factors related to inpatient admission within this population.
-
Podcast:
Trends in Adult Cancer鈥揜elated Emergency Department Utilization
Martin Scurr, PhD; Tom Pembroke, PhD, MD; Anja Bloom, PhD; et al.
open access
online only
JAMA Oncol. 2017;3(10):e172579. doi:10.1001/jamaoncol.2017.2579
This randomized clinical trial assesses the effect of modified vaccinia Ankara鈥�5T4, metronomic low-dose cyclophosphamide, or a combination of both treatments on antitumor immunity in patients with metastatic colorectal cancer.